Key result
Olmesartan treatment significantly improved fractional shortening (39.2% vs 14.4%, p<0.01) and attenuated oxidative stress, endoplasmic reticulum stress, and inflammatory cytokines in rats with experimental autoimmune myocarditis.
Why the study?
Does olmesartan improve myocardial function and reduce inflammatory and stress markers in rats with experimental autoimmune myocarditis?
Population
Lewis rats with experimental autoimmune myocarditis (EAM) induced by immunization with porcine cardiac myosin
Comparison
Olmesartan (10 mg/kg/day) for 21 days vs Vehicle for 21 days
Design
Preclinical
Follow-up
21 days
Authors
Loading...
Hypothesis-generating for ARB therapy in inflammatory myocarditis; human trials required before any clinical consideration.
Does olmesartan improve myocardial function and reduce inflammatory and stress markers in rats with experimental autoimmune myocarditis?
Absolute Event Rate: 39.2% vs 14.4%
p-value: p=<0.01
Olmesartan attenuates oxidative stress, ER stress, and inflammation, improving cardiac function in a rat model of autoimmune myocarditis.
Sukumaran et al. (2011) studied Experimental Autoimmune Myocarditis (EAM) (n=22). Olmesartan vs. Vehicle was evaluated on Fractional shortening (FS) (p=<0.01). Olmesartan treatment significantly improved fractional shortening (39.2% vs 14.4%, p<0.01) and attenuated oxidative stress, endoplasmic reticulum stress, and inflammatory cytokines in rats with experimental autoimmune myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: